Anna Skwarska

9PUBLICATIONS
73CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Free radical chemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 29, 2026
Specific F1 ATP synthase inhibition delivers transient mitochondrial stress for selective targeting of acute myeloid leukemia.

|Jul 23, 2026
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models.

|Mar 31, 2025
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.

Zhe Wang, Anna Skwarska, Gowri Poigaialwar

|Oct 12, 2023
BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs.

Anna Skwarska, Marina Konopleva

|Feb 15, 2022
The Role of Androgen Receptor and microRNA Interactions in Androgen-Dependent Diseases.

Agnieszka Bielska, Anna Skwarska, Adam Kretowski

|Jul 14, 2021
Zap-Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat.

Kathrin S Troelsen, Ewen D D Calder, Anna Skwarska

Pageof 2

Frequent Collaborators

6 joint publications

Marina Y Konopleva

2 joint publications

Magdalena Niemira

2 joint publications

Adam Krętowski

2 joint publications

Naveen Pemmaraju